CNBX News and Press, Cannabics Pharmaceuticals Inc From 06/17/21

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases PR Newswi...

Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program PR Newswire TEL AVIV , Israel and BETHESDA, Md., June 3, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of can...

Cannabics Pharmaceuticals (CNBX) announces that the European Patent Office has granted the company a pharmaceuticals patent for its personalized medicine drug discovery technology.The approved patent is titled: "System and Method for High Throughput Screening of Cancer Cells".Outside the...

The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology PR Newswire TEL AVIV , Israel and BETHESDA, Md., May 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CN...

Cannabics Pharmaceuticals (CNBX) announces that it has filed a patent application under the Patent Cooperation Treaty ((PCT)) for novel formulations developed for treatment of various cancer types.The patent application includes preclinical supporting data collected from in-vitro experim...

Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations PR Newswire TEL AVIV , Israel and BETHESDA, Md., May 11, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in th...

Cannabics Pharmaceuticals (CNBX) has received "Notice of Allowance" from the Mexican Patent and Trademark Office ((IMPI)) in relation to the company's patent titled: 'System and method for high throughput screening of cancer cells'.The decision of the Mexican patent authority follows the...

Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI) PR Newswire TEL AVIV , Israel and BETHESDA, Md., May 6, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global ...

Cannabics Pharmaceuticals ([[CNBX]]) announces the launch of a new research program for the development of a melanoma antitumor targeting medicine. Company highlights recent completion of a series of preclinical experiments within the company's in-house research facilities demo...

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, April 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC...